May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Intravitreal Bevacizumab (Avastin) for the Management of Refractory Pseudophakic Cystoid Macular Edema: 6 Month Results of the Pan American Collaborative Retina Study (PACORES) Group
Author Affiliations & Notes
  • L. Wu
    Vitreoretinal, Instituto De Cirugia Ocular, Plaza Mayor San Jose, Costa Rica
  • J. Arevalo
    Vitreoretinal, Clinica Oftalmologica Centro Caracas, Caracas, Venezuela
  • M. Maia
    Vitreoretinal, Universidade Federal de São Paulo - Departamento de Oftalmologia - Instituto da Visão, Sao Paulo, Brazil
  • R. A. Garcia-Amaris
    Vitreoretinal, Clinica Oftalmológica Centro Caracas, Caracas, Venezuela
  • J. Roca
    Vitreoretinal, Clinica Ricardo Palma, Lima, Peru
  • J. G. Sanchez
    Vitreoretinal, Clinica Oftalmológica Centro Caracas, Caracas, Venezuela
  • M. H. Berrocal
    Vitreoretinal, University of Puerto Rico, San Juan, Puerto Rico
  • Pan American Collaborative Retina Study (PACORES)Group
    Vitreoretinal, Instituto De Cirugia Ocular, Plaza Mayor San Jose, Costa Rica
  • Footnotes
    Commercial Relationships  L. Wu, None; J. Arevalo, None; M. Maia, None; R.A. Garcia-Amaris, None; J. Roca, None; J.G. Sanchez, None; M.H. Berrocal, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 3274. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      L. Wu, J. Arevalo, M. Maia, R. A. Garcia-Amaris, J. Roca, J. G. Sanchez, M. H. Berrocal, Pan American Collaborative Retina Study (PACORES)Group; Intravitreal Bevacizumab (Avastin) for the Management of Refractory Pseudophakic Cystoid Macular Edema: 6 Month Results of the Pan American Collaborative Retina Study (PACORES) Group. Invest. Ophthalmol. Vis. Sci. 2008;49(13):3274. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To determine the feasibility, safety and clinical effect of intravitreal (IVT) bevacizumab (Avastin) in patients with refractory cystoid macular edema (CME) after cataract surgery.

Methods: : Thirty-six eyes of 31 patients with a mean age of 69.5 years (range: 50 to 87 years) that were treated with at least one IVT injection of 1.25 mg or 2.5 mg of bevacizumab participated in this interventional retrospective multicenter study. Patients had a mean follow-up of 42.3 weeks (range: 24 to 80 weeks).

Results: : Twenty-five eyes (69.4%) demonstrated improvement of best-corrected visual acuity (BCVA) (≥2 ETDRS lines) and no eye experienced worsening of visual acuity (≥2 ETDRS lines). Mean baseline BCVA was 20/160 (logMAR = 0.92) and the mean final BCVA was 20/63 (logMAR = 0.55) (p < 0.0001). Optical coherence tomography (OCT) demonstrated that mean central macular thickness at baseline was 456.2 µm (range: 208 to 784 µm) and decreased to a mean of 262.9µm (range: 142 to 453 µm) at the end of follow-up (p < 0.0001). Twenty (55.5%) eyes needed a second injection, nine (25%) needed a third injection, and five (13.9%) needed a fourth injection. The mean interval between injections was 17.6 weeks (range: 6 to 45 weeks). No ocular or systemic adverse events were observed.

Conclusions: : Short-term results suggest that IVT bevacizumab is well tolerated in patients with refractory pseudophakic CME. Treated eyes had a significant improvement in BCVA and decrease in macular thickness by OCT.

Keywords: macula/fovea • edema • retina 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×